Iniciace protidestičkové léčby u pacienta s STE · Iniciace protidestičkové léčby u pacienta s STE infarktem myokardu? AKUTNÍ IM • ZVÝŠENÁ REAKTIVITA DESTIČEK ... prasugrel

Prof. MUDr. Jan F Vojáček DrSc, FESC, FACC

Iniciace protidestičkové

léčby u pacienta s STE

infarktem myokardu?

AKUTNÍ IM

• ZVÝŠENÁ REAKTIVITA DESTIČEK

• ZVÝŠENÁ TROMBOGENICITA

• NEDOSTATEČNĚ ÚČINNÁ PROTIDESTIČKOVÁ LÉČBA

AKUTNÍ IM

• ZVÝŠENÁ REAKTIVITA DESTIČEK

• ZVÝŠENÁ TROMBOGENICITA

• NEDOSTATEČNĚ ÚČINNÁ PROTIDESTIČKOVÁ LÉČBA

All patients treated with ticagrelor had PR below 208 PRU cut-off point, whereas more than half of patients (62.50%) receiving high-dose clopidogrel remained non-responsive to clopidogrel.

ETAMI-Study

ETAMI-Study: Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute Myocardial

Infarction; NCT01327534) (J Am Coll Cardiol Intv 2015;8:147–54

ETAMI-Study



ETAMI-Study



ETAMI-Study



ETAMI-Study



ETAMI-Study



ETAMI-Study



ETAMI-Study



ETAMI-Study

CONCLUSIONS The pre-PCI administration of prasugrel in patients with STEMI undergoing PPCI was associated with a significant faster platelet inhibition compared with clopidogrel. Therefore, prasugrel should be preferred to clopidogrel in this setting.



PLATELET FUNCTION IN PATIENTS WITH STEMI

full effect of prasugrel or ticagrelor on platelet function may take several hours in patients with STEMI

Alexopoulos D et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segmentelevation myocardial infarction. CircCardiovasc Interv 2012;5:797-804. Parodi Get al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601-6.

MOŽNOSTI ANTITROMBOTICKÉ LÉČBY

HEPARIN

HEPARIN + GP IIb/IIIa

BIVALURIDIN

ENOXAPARIN i.v.

ENOXAPARIN + GP IIb/IIIa

ASA nasycovací a udržovací

ASA + klopidogrel

ASA + prasugrel

ASA + ticagrelor

ANTITROMBOTIKA VE TŘÍDĚ I U STEMI

SOUČINNOST PROTIDESTIČKOVÉ A ANTIKOAGULAČNÍ LÉČBY

MOŽNOSTI ANTITROMBOTICKÉ LÉČBY

JAKÁ KOMBINACE ???

KDY ???

čas

trombogenicita

AIM

čas

trombogenicita

ANTITROMBOTIKA

AIM

čas

trombogenicita

riziko krvácení

ANTITROMBOTIKA

AIM

čas

trombogenicita

riziko krvácení

ANTITROMBOTIKA ANTITROMBOTIKA

AIM

ATLANTIC

1862 patients with ongoing STEMI of less than 6 hours’ duration, comparing prehospital (in the ambulance) versus in-hospital (in the catheterization laboratory) treatment with ticagrelor

median time from randomization to angiography was 48 minutes, and the median time difference between the two treatment strategies was 31 minutes

ATLANTIC

ATLANTIC

ATLANTIC

rates of major adverse cardiovascular events did not differ significantly between the two study groups

rates of major bleeding events were low and virtually identical in the two groups

ATLANTIC

absence of ST-segment elevation resolution of 70% or greater after PCI (a secondary end point) was reported for 42.5% and 47.5% of the patients, respectively

rates of definite stent thrombosis were lower in the prehospital group than in the in-hospital group (0% vs. 0.8% in the first 24 hours; 0.2% vs. 1.2% at 30 days)

ATLANTIC

ARIAM-Andalucía Registry

Almendro-Delia M Am J Cardiol 2015;115:1019e1026


The results of our study confirm the benefit of pretreatment

with clopidogrel in reducing ischemic events and mortality during hospitalization, although only in the subgroup with STEMI. This benefit was associated with an increase

in minor bleeding but proving to be a net clinical benefit strategy Almendro-Delia M Am J Cardiol 2015;115:1019e1026



with clopidogrel in reducing ischemic events and mortality during hospitalization, although only in the subgroup with STEMI. This benefit was associated wih an increase


t



with clopidogrel in reducing ischemic events and mortality during hospitalization, although only in the subgroup with STEMI. This benefit was associated wih an increase


t

Bellemain-Appaix A et al. Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. JAMA 2012;308(23):2507–2516.

Zeymer U et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012;101(4):305–312.

Koul S. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2011;32(23): 2989–2997.

Dorler J. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 2011;32(23):2954–2961.

HEALTH TECHNOLOGY ASSESSMENT VOLUME 19 ISSUE 29 APRIL 2015 ISSN 1366-5278

those aged < 75 years who weighed > 60 kg (no previous stroke or transient ischaemic attack). For the

primary composite end point (death from CV causes, non-fatal myocardial infarction or non-fatal stroke)

statistically significantly fewer events occurred in the prasugrel arm (8.3%) than in the clopidogrel arm (11%)

there was a significant

difference in favour of clopidogrel when major and minor bleeding events were combined (3.0 vs. 3.9%)

Lack of

data precluded a clinical comparison of prasugrel with ticagrelor; the comparative effectiveness of

prasugrel compared with ticagrelor therefore remains unknown.

Well-audited data are needed from a

long-term UK clinical registry on defined ACS patient groups treated with PCI who receive prasugrel,

ticagrelor and clopidogrel.

HEALTH TECHNOLOGY ASSESSMENT VOLUME 19 ISSUE 29 APRIL 2015 ISSN 1366-5278

The results of sensitivity analyses confirmed that it is likely

that, for all four ACS subgroups, within 5–10 years prasugrel is a cost-effective treatment option compared

with clopidogrel at a willingness-to-pay threshold of £20,000 to £30,000 per QALY gained. At the full

40-year time horizon, all estimates are < £10,000 per QALY gained

INICIACE PROTIDESTIČKOVÉ LÉČBY U STEMI

• VYSOKÉ TROMBOTICKÉ RIZIKO V PRVNÍCH FÁZÍCH STEMI

– CO NEJDŘÍVE PO PRVNÍM KONTAKTU S

NEMOCNÝM

– PREFERENČNĚ PRASUGREL nebo TICAGRELOR

– SOUČASNĚ PLNÁ ANTIKOAGULAČNÍ LÉČBA

• V DALŠÍCH FÁZÍCH PŘEVAŽUJE KRVÁCIVÉ RIZIKO A PŘÍPADNÉ JINÉ VEDLEJŠÍ ÚČINKY

– PODLE TOHO ÚPRAVA TRVÁNÍ A ZPŮSOBU

ANTITROMBOTICKÉ LÉČBY

• TÉMA DALŠÍHO SDĚLENÍ

ZÁVĚR

AKUTNÍ IM • CLOPIDOGREL

– POMALÝ NÁSTUP, U IM EFEKTIVITA < 50 %

• PRASUGREL

– NELZE U OSOB > 75 let, < 60 kg, po TIA, CMP

• TICAGRELOR – PŘI DLOUHODOBÉM PODÁVÁNÍ časté

předčasné vysazení, vyšší výskyt rakoviny

Serebruany V L. Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events. International Journal of Cardiology 201, 15 December 2015, Pages 508–512

Iniciace protidestičkové léčby u pacienta s STE · Iniciace protidestičkové léčby u pacienta s STE infarktem myokardu? AKUTNÍ IM • ZVÝŠENÁ REAKTIVITA DESTIČEK ... prasugrel

Documents